Bintie Biotech

Bintie Biotech is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on pioneering next-generation cell therapies for solid tumors. The company utilizes proprietary technology to engineer CAR-T cells with improved infiltration and sustained activity in the challenging tumor microenvironment. Its lead program, BT-001, targets Claudin 18.2 and is currently undergoing Phase 1 clinical evaluation for patients with advanced gastric and pancreatic cancers. By integrating advanced genetic engineering with deep insights into T-cell biology, Bintie Biotech seeks to expand the reach of immunotherapy beyond hematological malignancies.